RNS Number:5195J
Protherics PLC
02 April 2003

                                                                    2 April 2003

                                 PROTHERICS PLC

                Trading Update for the year ended 31 March 2003


Protherics PLC, ("Protherics" or the "Company") the UK biopharmaceutical
company, today announces its review of trading for the second half of the year
ended 31 March 2003. Since reporting its interim results on 3rd December 2002,
the Company expects to have traded profitably over the final six months of the
year. The loss for the full year is anticipated to be within the range of market
estimates.

This anticipated trading performance has been achieved despite a lower than
expected turnover in the full year. Production activity for CroFab(TM) has been
particularly concentrated approaching the start of the spring "biting season".
The final three batches of CroFab(TM) manufactured in the financial year 2002/
2003 are now to be released to the market early in the financial year 2003/2004. 
The first of these three batches was released on 1 April 2003 and the remaining 
two will be released in time for the snake bite season.

The impact of delayed sales is expected to be largely offset by improved margins
and lower operating costs. The reduced revenue in the year ended 31 March 2003
is expected to create a matching benefit in the first half of the new financial
year.


For further information contact:

Protherics PLC
Andrew Heath                   Chief Executive             +44 (0) 20 7246 9950
                                                           +44 (0) 7919 480 510
Barry Riley                    Finance Director            +44 (0) 1928 518 003


The Maitland Consultancy
Brian Hudspith                                             +44 (0) 20 7379 5151
Simone Cheetham


Protherics PLC


Protherics is an international biopharmaceutical company, whose platform
technology is the development and production of immunotherapeutics. Protherics'
product portfolio includes two products which have received US Food and Drug
Administration (FDA) approval - CroFab(TM) , a rattlesnake antivenom, and
DigiFab(TM) (Digoxin Immune Fab (Ovine), a treatment for digoxin toxicity.

The Company's ordinary shares are listed on the Official List of the UK Listing
Authority and are traded on the London Stock Exchange. (PTI.L)

An electronic version of this will be available at: www.protherics.com

This release, and oral statements made from time to time by Company
representatives concerning the subject matter hereof, may contain so-called
"forward looking statements". These statements can be identified by introductory
words such as "expects", "plans", "will", "estimates", "forecasts", "projects",
words of similar meaning, and by the fact that they do not relate strictly to
historical or current facts. Forward-looking statements frequently are
discussing the Company's growth strategy, operating and financial goals, plans
relating to regulatory submissions and approvals and development programs. Many
factors may cause actual results to differ from the Company's forward-looking
statements, including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not. Those and
other risks are described in the Company's filings with the Securities and
Exchange Commission, copies of which are available from the SEC or may be
obtained upon request from the Company. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing undue
reliance on such statements.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
TSTUAAWROARSRAR